Johnson & Johnson (NYSE:JNJ) is Wahed Invest LLC's 10th Largest Position

Wahed Invest LLC increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 6.5% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 62,108 shares of the company's stock after acquiring an additional 3,807 shares during the period. Johnson & Johnson makes up about 1.5% of Wahed Invest LLC's holdings, making the stock its 10th largest holding. Wahed Invest LLC's holdings in Johnson & Johnson were worth $8,982,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Principal Financial Group Inc. boosted its position in shares of Johnson & Johnson by 10.5% during the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company's stock worth $562,723,000 after purchasing an additional 329,473 shares during the period. Invst LLC raised its holdings in shares of Johnson & Johnson by 394.0% in the 3rd quarter. Invst LLC now owns 10,290 shares of the company's stock valued at $1,668,000 after buying an additional 8,207 shares during the period. McIlrath & Eck LLC raised its holdings in shares of Johnson & Johnson by 10.7% in the 3rd quarter. McIlrath & Eck LLC now owns 2,892 shares of the company's stock valued at $469,000 after buying an additional 279 shares during the period. Passumpsic Savings Bank purchased a new position in Johnson & Johnson during the 3rd quarter valued at about $262,000. Finally, Te Ahumairangi Investment Management Ltd increased its stake in Johnson & Johnson by 10.1% during the third quarter. Te Ahumairangi Investment Management Ltd now owns 50,765 shares of the company's stock worth $8,180,000 after purchasing an additional 4,640 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Bank of America cut their price objective on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, April 10th. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Stifel Nicolaus reduced their price target on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research report on Thursday, January 23rd. Finally, The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their target price for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $171.82.

Johnson & Johnson Stock Performance

NYSE:JNJ traded up $1.63 during mid-day trading on Friday, reaching $156.09. 5,973,317 shares of the stock were exchanged, compared to its average volume of 7,885,287. The stock has a market capitalization of $375.56 billion, a P/E ratio of 23.47, a P/E/G ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a 50 day simple moving average of $158.85 and a 200-day simple moving average of $154.61. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.33%. The ex-dividend date of this dividend is Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.